GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Dignitana AB (OTCPK:DIZTF) » Definitions » LT-Debt-to-Total-Asset

Dignitana AB (Dignitana AB) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Dignitana AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Dignitana AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Dignitana AB's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).


Dignitana AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Dignitana AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dignitana AB LT-Debt-to-Total-Asset Chart

Dignitana AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.01 0.22 0.15 0.14

Dignitana AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.14 -

Dignitana AB LT-Debt-to-Total-Asset Calculation

Dignitana AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )/Total Assets (A: Dec. 2023 )
=0.592/4.371
=0.14

Dignitana AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )=Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )/Total Assets (Q: Mar. 2024 )
=0/4.297
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Dignitana AB  (OTCPK:DIZTF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Dignitana AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Dignitana AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Dignitana AB (Dignitana AB) Business Description

Traded in Other Exchanges
Address
Traktorgranden 3, Lund, SWE, 226 60
Dignitana AB is a medical technology company, that develops, produces, and markets The DigniCap Scalp Cooling System. It is a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy to improve well-being and quality of life. Geographically, it derives a majority of revenue from the USA.